Literature DB >> 18781673

Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.

Anthony A Grace1.   

Abstract

Dopamine (DA) neurons exist in two activity states; either spontaneously firing or quiescent and nonfiring. When faced with a behavioral demand, the quiescent DA neurons can be activated to facilitate normal motor output. Levodopa appears to increase DA output by activating these nonfiring neurons; as a consequence, DA release is increased, but behavioral demand can now overwhelm the system, potentially leading to the inactivation and on/off phenomena. Levodopa administered in a pulsatile manner may also lead to the induction of synaptic plasticity within the DA systems. In the ventral mesolimbic system, this could lead to the loss of behavioral flexibility, impulsive behavior, and cognitive impairment, whereas in the dorsal nigrostriatal system, this may underlie Levodopa-induced dyskinesia. Continuous administration of Levodopa may circumvent this sensitization process, enabling a therapeutic response without limbic and motor side effects. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781673     DOI: 10.1002/mds.22020

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Levodopa increases speed of alternating movements in Parkinson's disease patients.

Authors:  Thomas Müller; Sören Peters; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2012-06-22       Impact factor: 3.575

Review 2.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors.

Authors:  Andrea Anzalone; José E Lizardi-Ortiz; Maria Ramos; Claudia De Mei; F Woodward Hopf; Ciro Iaccarino; Briac Halbout; Jacob Jacobsen; Chisato Kinoshita; Marc Welter; Marc G Caron; Antonello Bonci; David Sulzer; Emiliana Borrelli
Journal:  J Neurosci       Date:  2012-06-27       Impact factor: 6.167

Review 4.  Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

Review 5.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

6.  L-dopa treatment duration versus Parkinson's disease progression: the dorsal-ventral divide.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  Mov Disord       Date:  2013-02-07       Impact factor: 10.338

Review 7.  The dopaminergic basis of human behaviors: A review of molecular imaging studies.

Authors:  Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

Review 8.  The Renin-Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene.

Authors:  Tamara Kobiec; Matilde Otero-Losada; Guenson Chevalier; Lucas Udovin; Sofía Bordet; Camila Menéndez-Maissonave; Francisco Capani; Santiago Pérez-Lloret
Journal:  Front Synaptic Neurosci       Date:  2021-04-22

9.  Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease.

Authors:  Andrew D Lawrence; David J Brooks; Alan L Whone
Journal:  Front Psychol       Date:  2013-02-27

Review 10.  Neural correlates of motor vigour and motor urgency during exercise.

Authors:  H G Laurie Rauch; Georg Schönbächler; Timothy D Noakes
Journal:  Sports Med       Date:  2013-04       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.